Leo starts Phase III trial of tralokinumab for atopic dermatitis

Leo Pharma A/S (Ballerup, Denmark) began a Phase III trial of tralokinumab (CAT-354) to treat atopic dermatitis in patients who are candidates for systemic therapy. The co-primary endpoints of the double-blind, placebo-controlled trial are the proportion of patients with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear) point at week 16 and the proportion of patients achieving a ≥75% reduction in Eczema Area and Severity Index (EASI). Secondary endpoints include the change from baseline to week 16 in Dermatology Life Quality Index (DLQI) and Scoring Atopic Dermatitis (SCORAD) scores...